Compare Koninklijke Philips NV (PHG) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Rocket Lab USA Inc — how do they compare? Koninklijke Philips NV trades at $26.3 (market cap $25.89B), while Rocket Lab USA Inc trades at $69.45 (market cap $43.19B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Koninklijke Philips NV pays a 3.81% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| PHG | RKLB | |
|---|---|---|
Market Cap | $25.89B | $43.19B |
Sector | Health | Technology |
52-Week High | $32.91 | $150.23 |
52-Week Low | $25.02 | $39.48 |
Enterprise Value | $32.18B | $41.94B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $26.58, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported net income of $895 million in 2025, a significant recovery from prior losses, with a net margin of 5.5%. Recent FDA clearances for medical devices and AI integrations highlight ongoing innovation. Cash flow from operations remains positive at $1.17 billion for 2025, though net cash flow declined to $403 million.
The outlook is mixed: analyst consensus is neutral with 59% hold ratings, reflecting caution despite recent profitability improvements. Key risks include high debt levels, with debt-to-asset ratio at 25.44% in 2025, and competitive pressures in health technology. Upside potential hinges on execution of AI-driven growth initiatives and margin expansion, as noted in Seeking Alpha analysis on 2026-05-20.
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, with a bearish technical signal despite oscillators suggesting oversold conditions. The company reported a net loss of $198.21 million in 2025, though revenue grew to $601.80 million. Recent positive news includes a $266 million defense contract awarded on July 21, 2026, per Benzinga, providing a near-term catalyst amid broader sector volatility.
The outlook remains high-risk with negative profitability but strong analyst support; 75% recommend Buy with a $116.90 consensus target. Key risks include execution delays on the Neutron rocket and intense competition. Upside depends on contract execution and path to profitability, while downside stems from cash burn and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
